Liwei Jia^*, Dongying Lv^†, Shuang Zhang^*, Zhenyue Wang^*, Bo Zhou^*

Oncology Research, Vol.27, No.4, pp. 503-508, 2019, DOI:10.3727/096504018X15344989701565

Abstract Astragaloside IV (AS-IV) is an active ingredient in Astragalus membranaceus and is involved in various biological processes, such as regulating the immune system, and counteracting inflammation and malignancy. The aim of this study was to explore the effect of AS-IV on non-small cell lung cancer (NSCLC) cells. Cell counting kit (CCK)-8 assay and flow cytometry were performed to investigate cell survival and cell death, and Western blotting was performed to assess protein expression. We found that AS-IV inhibited the migration and proliferation of NSCLC cells and caused a noticeable increase in cell death. Furthermore, the expression of Bax, a marker… More >

Lu Guo^*, Duankai Chen^†, Xing Yin^‡, Qingfeng Shu^†

Oncology Research, Vol.27, No.4, pp. 487-494, 2019, DOI:10.3727/096504018X15323394008784

Abstract GSK-3 is a versatile protein kinase participating in many reactions. Currently, there is insufficient understanding of its influence on breast cancer (BC). In order to explore its influence on migration and invasion in BC, we investigated its expression in BC cell lines using qRT-PCR and Western blot (WB). Immunohistochemistry (IHC) was used to examine the potential of GSK-3 to predict clinical outcome in BC patients. GSK-3 knockdown was achieved using an shRNA plasmid vector in T47D cells. Our research explored the biological reactions and downstream pathways involved. We found excessive GSK-3 expression in BC tissues, which was correlated with worse… More >